What Can You Expect at the 6th RNA Editing Summit?
With clinical data now illuminating the significant therapeutic possibilities of RNA editing, this year’s 6th RNA Editing Summit returns to deliver a cutting-edge program built with the most innovative experts in RNA.
Sharing critical insights on enhancing editing efficiency, limiting off-target effects, expanding therapeutic targets, and streamlining translation, this meeting will empower you to drive your RNA modifying candidates to clinically and commercially successful therapies, accelerating access to patients in need.
Unmissable Agenda Highlights
CEO & Investment Panel
Strategize for success with lessons from investment experts and insights from CEOs who have successfully secured funding for their investigational RNA editors, allowing you to attract investment and industry collaborations.
Hear from:
- Roger Song, Senior Equity Research Analyst, Jefferies
- Keay Nakae, Director of Research, Chardan
- Steve Seedhouse, Biotechnology Equity Research, Cantor Fitzgerald
- Ram Aiyar, Chief Executive Officer, Korro Bio
- Peter Nell, CEO, Stealth Biotech
- Paul Bolno, CEO, Wave Life Sciences
Expanding Therapeutic Targets for RNA Editing
Reach more patients in need by differentiating and expanding the range of indications RNA editing could successfully treat, and explore the biological progress necessary to apply RNA modification to treating common diseases.
Insights from:
- Tehmina Masud, Vice President & Head of Systems & Target Biology, Deep Genomics
- Andrew Fraley, Chief Innovation Officer, Radar Therapeutics
- Gerard Platenburg, Chief Scientific Officer, ProQR Therapeutics
- Vincent DiGiacomo, Director, Therapeutic Innovation, Jorna Therapeutics
Deep Dive into the Biology of ADAR & Novel Editing Technologies
Enhance editing efficiency and precise delivery of RNA editing payloads by deepening your knowledge of RNA and ADAR, and expand the therapeutic possibilities of editing with novel technologies including multi-kilobase RNA editing, CRISPR-based editing, and beyond.
Lessons from:
- Jacob Borrajo, Founder & Chief Executive Officer, Amber Bio
- Artem Nemudryi, Assistant Professor, University of Florida
- Peter Beal, Professor, UC Davis
- Chad Weldy, Instructor, Cardiovascular Medicine, Stanford University
- Yang Gao, Assistant Professor, Rice University
Streamline Translation by Overcoming Hurdles to the Clinic
Successfully navigate regulatory guidance to drive the development of your investigational editors, overcome preclinical challenges, and hear first-hand insights straight from the clinic to power your own pipeline.
Learn from:
- Venkat Krishnamurthy, Senior Vice President & Head of Platform, RNA Editing, Korro Bio
- TJ Cradick, Chief Technology Officer, HuidaGene Therapeutics
- Robert Deans, Chief Technology Officer, Rett Syndrome Research Trust
Explore the Full Event Guide
- 60+ World-Leading RNA Experts
- 3 Days of Data-Driven RNA Editing Insights & Technologies
- Meaningful Networking Sessions to Drive Important Industry Connections
- CEOs' & Investor Panel Discussion
- Only Forum Exclusively Focused on Progressing RNA Editing Therapies
Attending Companies Include
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive regulatory insights during our packed agenda, interactive roundtables, and new CXOs’ panel discussion.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.